Visual Function Changes After Intraocular Pressure Reduction
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00435058 |
Recruitment Status :
Completed
First Posted : February 14, 2007
Last Update Posted : February 19, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Glaucoma | Drug: timolol maleate 0,5% Drug: brimonidine tartrate 0,2% Drug: travoprost 0,004% | Not Applicable |
Primary open angle glaucoma patients without use of antiglaucoma medications will be enrolled in this study. After inclusion, the patients will randomly receive one of three antiglaucoma medications (timolol maleate 0,5%, brimonidine tartrate 0,2% or travoprost 0,004%) in one randomly selected eye.
The patients will be evaluated with Goldmann applanation tonometry, visual acuity test, contrast sensitivity test, visual quality perception test (visual analogue scale) and standard automated perimetry before and after 4 weeks of glaucoma treatment onset.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 54 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single |
Primary Purpose: | Treatment |
Official Title: | Visual Function Changes After Intraocular Pressure Reduction Using Antiglaucoma Medications: A Randomized Clinical Trial |
Study Start Date : | September 2005 |
Study Completion Date : | April 2006 |
- intraocular pressure
- contrast sensitivity
- visual quality perception
- Mean deviation of the visual field (MD)
- Pattern Standard Deviation of the visual field (PSD)
- visual acuity

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Primary open angle glaucoma
- Intraocular pressure greater than 21 mmHg
Exclusion Criteria:
- Best corrected visual acuity (BCVA) worse than 20/80
- Significant media opacity
- History of steroid use

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00435058
Principal Investigator: | Tiago Prata, MD | Federal University of Sao Paulo | |
Principal Investigator: | Luiz A Melo Jr, MD | Federal University of Sao Paulo |
ClinicalTrials.gov Identifier: | NCT00435058 |
Other Study ID Numbers: |
CEP 1021/05 |
First Posted: | February 14, 2007 Key Record Dates |
Last Update Posted: | February 19, 2007 |
Last Verified: | February 2007 |
intraocular pressure contrast sensitivity visual function |
Glaucoma Ocular Hypertension Eye Diseases Timolol Brimonidine Tartrate Travoprost Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists |